AstraZeneca made an acquisition proposal worth approximately US$10 billion to US-based Rhythm Pharmaceuticals. The proposal has been reported as part of the race for drugs for rare metabolic diseases.
UK pharmaceutical major AstraZeneca made an acquisition proposal worth approximately US$10 billion to US biotech company Rhythm Pharmaceuticals. The detailed terms and the likelihood of completion were not specified in the article.
The move has been reported as one of a series of partnerships and acquisitions among major companies involving the development and marketing of drugs focused on rare metabolic diseases. Further reports are awaited regarding Rhythm Pharmaceuticals’ drug-development progress and future response.